Showing results (111-120 of 134) with videos related to

Sort By:
Pageof 14
JCI Insight|March 31, 2022
Plasma metabolomics reveals disrupted response and recovery following maximal exercise in myalgic encephalomyelitis/chronic fatigue syndromeArnaud Germain, Ludovic Giloteaux, Geoffrey E Moore, et al.
Cancer Treatment Reviews|February 28, 2012
Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trialsJohn R Mackey, Robert S Kerbel, Karen A Gelmon, et al.
Cancer Research|August 4, 2004
Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progressionAruna Somasiri, Julie S Nielsen, Nikita Makretsov, et al.
Investigational New Drugs|January 8, 2020
Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysisJean-Michel Lavoie, Teresa Mitchell, Sung-Eun Lee, et al.
Journal of the National Cancer Institute|May 14, 2009
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancerMaggie C U Cheang, Stephen K Chia, David Voduc, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 23, 2006
Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survivalMaggie C U Cheang, Diana O Treaba, Caroline H Speers, et al.
Bone Marrow Transplantation|July 28, 2010
Graft-vs-tumor effect in patients with advanced nasopharyngeal cancer treated with nonmyeloablative allogeneic PBSC transplantationH C Toh, W K Chia, L Sun, et al.
Health and Quality of Life Outcomes|February 16, 2019
Development and evaluation of a quality of life measurement scale in English and Chinese for family caregivers of patients with advanced cancersYin Bun Cheung, Shirlyn H S Neo, Irene Teo, et al.
Breast Cancer Research : BCR|May 4, 2017
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancerStephen K Chia, Susan L Ellard, Mihaela Mates, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 18, 2020
ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT TrialsNicholas C Turner, Claire Swift, Lucy Kilburn, et al.
Pageof 14